In vitro release studies on matrix type transdermal drug delivery systems of naltrexone and its acetyl prodrug

Drug Development and Industrial Pharmacy

Volumn 31, Issue 9, 2005, Pages 871-877

  Nalluri, Buchi N ^a   Milligan, Caitlin ^a   Chen, Jianhong ^a   Crooks, Peter A ^a   Stinchcomb, Audra L ^a  

^a University of Kentucky   (United States)

Author keywords

Drug in adhesive patches; In vitro release testing; Naltrexone; Prodrugs

Indexed keywords

3 O ACETYL ESTER DERIVATIVE; DURO TAK; NALTREXONE; NALTREXONE DERIVATIVE; POLYMER; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CORRELATION ANALYSIS; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG RELEASE; DRUG SYNTHESIS; IN VITRO STUDY; TRANSDERMAL DRUG ADMINISTRATION; TRANSDERMAL PATCH;

ACETYLATION; ADMINISTRATION, CUTANEOUS; ALGORITHMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIFFUSION; NALTREXONE; NARCOTIC ANTAGONISTS; PRODRUGS; SOLVENTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 27544487604     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500271944     Document Type: Article

References (12)

1. Chen, Y. L., Chun, L. L., & Enscore, D. J. (March 4, 1986). Transdermal Therapeutic Systems for the Administration of Naloxone, Naltrexone, and Nalbuphine. Alza US Patent 4,573,995.
2. Cone, E. J., Gorodetzky, C. W., & Yeh, S. Y. (1974). The urinary excretion profile of naltrexone and metabolites in man. Drug Metab. Dispos., 2, 506-512.
3. Hussain, M. A., Koval, C. A., Myers, M. J., Shami, E. G., & Shefter, E. (1987). Improvement of the oral bioavailability of naltrexone in dogs. J. Pharm. Sci., 76, 356-358.
4. Hussain, M. A., Aungst, B. J., Koval, C. A., & Shefter, E. (1988). Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs. Pharm. Res., 5, 615-618.
5. Kranzler, H. R., Lowe, V. M., & Kirk, J. V. (2000). Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology, 22, 493-503.
6. Meyer, M. C., Straughn, A. B., Lo, M. W., Schary, W. L., & Whitney, C. C. (1984). Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J. Clin. Psychiatry, 45, 15-19.
7. Pillai, O., Hamad, M. O., Crooks, P. A., & Stinchcomb, A. L. (2004). Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone. Pharm. Res., 21, 1146-1152.
8. Stinchcomb, A. L., Swaan, P. W., Ekabo, O., Harris, K. E., Browe, J., Hammell, D. C., Cooperman, T. A., & Pearsall, M. (2002). Straight-chain naltrexone ester prodrugs: diffusion and concurrent biotransformation in human skin. J. Pharm. Sci., 91, 2571-2578.
9. Terenius, L. (1998). Rational treatment of addiction. Curr. Opin. Chem. Biol., 2, 541-547.
10. Vereby, K., Volavka, J., Mule, S. J., & Resnick, R. B. (1976). Naltrexone: disposition, metabolism and effects after acute and chronic dosing. Clin. Pharmacol. Ther., 20, 315-328.
11. Volpicelli, J. R., Alterman, A. I., & Hayashida, M. (1992). Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry, 49, 876-880.
12. Wall, M., Brine, D. R., & Perez Reyes, M. (1981). Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab. Dispos., 9, 369-375.